Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed. Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement […]